High-dose lymphoablative therapy (HDLT) with or without autologous stem-cell rescue for treatment of severe autoimmune diseases.

High-dose lymphoablative therapy (HDLT) with or without autologous stem-cell rescue for treatment of severe autoimmune diseases. [electronic resource] - Tecnologica. MAP supplement. Blue Cross and Blue Shield Association. Medical Advisory Panel Dec 2001 - 29-9 p. digital

Publication Type: Journal Article


Antilymphocyte Serum--administration & dosage
Autoimmune Diseases--mortality
Blue Cross Blue Shield Insurance Plans
Cyclophosphamide--administration & dosage
Hematopoietic Stem Cell Transplantation--adverse effects
Humans
Immunosuppressive Agents--administration & dosage
Insurance Coverage
Technology Assessment, Biomedical
Transplantation, Autologous
Treatment Outcome
United States
United States Food and Drug Administration